Tuesday, May 19

Rivus Pharmaceuticals will push HU6 into Phase III development and is looking to engage with regulatory authorities and launch a late-stage study next year in obesity-related heart failure with preserved ejection fraction.

Read more about this post on Biospace

Leave A Reply